The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
by Roger Longman
The drug industry faces two cliffs. The first, and better known, is the generic cliff: $58.2 billion in US drug...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.
